Paul Choi
Stock Analyst at Goldman Sachs
(3.16)
# 1,117
Out of 5,148 analysts
106
Total ratings
52.24%
Success rate
0.58%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $9.24 | +29.87% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $40.42 | +135.03% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $61.43 | +54.65% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $66.37 | -24.66% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $65.50 | +52.67% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $46.00 | +19.57% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $13.39 | -55.19% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $76.30 | +0.92% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $29.70 | -32.66% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $41.03 | +14.55% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $13.93 | -13.85% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $19.02 | -84.23% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.43 | +1,766.54% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $11.46 | -56.37% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $42.55 | +22.21% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $9.34 | +124.84% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.27 | -8.26% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $242.09 | -7.06% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.90 | +36.74% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.76 | +229.86% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.80 | +1,288.89% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $11.81 | +1,339.46% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $6.42 | +24.61% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $132.38 | +1.98% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $68.36 | +338.85% | 2 | Mar 30, 2020 |
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $9.24
Upside: +29.87%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $40.42
Upside: +135.03%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $61.43
Upside: +54.65%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $66.37
Upside: -24.66%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $65.50
Upside: +52.67%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $46.00
Upside: +19.57%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $13.39
Upside: -55.19%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $76.30
Upside: +0.92%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $29.70
Upside: -32.66%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $41.03
Upside: +14.55%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $13.93
Upside: -13.85%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $19.02
Upside: -84.23%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.43
Upside: +1,766.54%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.46
Upside: -56.37%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $42.55
Upside: +22.21%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $9.34
Upside: +124.84%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.27
Upside: -8.26%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $242.09
Upside: -7.06%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.90
Upside: +36.74%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.76
Upside: +229.86%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.80
Upside: +1,288.89%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $11.81
Upside: +1,339.46%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $6.42
Upside: +24.61%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $132.38
Upside: +1.98%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $68.36
Upside: +338.85%